CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Virobay Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Virobay Inc.
1360 Willow Road
Phone: (650) 833-5700p:650 833-5700 Menlo Park, CA  94025-1524  United States Fax: (650) 833-6892f:650 833-6892
Virobay Inc filed a Registration Withdrawal Request of its Form S-1 (File No. 333-198672) with the SEC on 10/31/2014.
Business Summary
Virobay, Inc. is a clinical-stage biopharmaceutical company. The Company utilizes its cysteine cathepsin platform for the development and commercialization of drugs. Its programs are focused on addressing unmet medical needs for the treatment of neuropathic pain, autoimmune diseases and fibrosis. The Company applies scientific, clinical and commercial criteria in choosing which programs to advance. The Company’s VBY-036 is a selective cathepsin S inhibitor under development as an oral treatment for neuropathic pain and autoimmune diseases. Its VBY-891 is a selective cathepsin S inhibitor under development as an oral treatment for psoriasis. Its VBY-376 is a selective cathepsin B inhibitor under development as an oral treatment of liver fibrosis in patients with nonalcoholic steatohepatitis (NASH). Its VBY-825 is an inhibitor of multiple cathepsins, including cathepsins S and B, under development as an oral treatment for primary biliary cirrhosis (PBC).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201412/31/2013YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Senior Vice President, Project Management and Operations Kyle C.Elrod 47 1/1/2014
Vice President, Biology LeslieHolsinger 49
Vice President, Chemistry, Manufacturing and Controls AnanthaSudhakar 56
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 8 (As of 8/31/2014)
Outstanding Shares: 12,998,748 (As of 10/16/2014)
Stock Exchange: NASD
Federal Tax Id: 204905672
Fax Number: (650) 833-6892


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023